Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 9/20 | 1.00 |
| ▸ | PARP1 | P09874 | 5/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232829 | 0.79 | PDPK1 (0.66) | PDPK1PARP1DAPK3PRKD3PIM1 | |
| SCHEMBL19073287 | 0.78 | PDPK1 (0.64) | PDPK1PARP1DAPK3PRKD3PIM1 | |
| SCHEMBL1850150 | 0.71 | PDPK1 (1.00) | PDPK1PIM1PIM3CLK4 | |
| SCHEMBL25170501 | 0.70 | PDPK1 (0.54) | PDPK1PARP1TNKSTNKS2 | |
| SCHEMBL2369000 | 0.70 | GAA (0.60) | PDPK1PARP1GAA | |
| SCHEMBL4208195 | 0.69 | PDPK1 (0.74) | PDPK1DAPK3PRKD3PIM1GSK3A | |
| SCHEMBL17969217 | 0.69 | PDPK1 (0.74) | PDPK1GAA | |
| SCHEMBL7227346 | 0.68 | PDPK1 (0.51) | PDPK1PARP1DAPK3PRKD3PIM1 | |
| SCHEMBL16152543 | 0.68 | PDPK1 (0.51) | PDPK1PARP1PIM1CDC7PIM2 | |
| SCHEMBL4207656 | 0.67 | PARP1 (0.54) | PDPK1PARP1DAPK3PRKD3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4100015-A1 | COMBINATION THERAPY FOR TREATING MPS1 | Gain Therapeutics SA (CH) | 2022-12-14 | — | — | EP | disclosed |
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| EP-3617213-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2020-03-04 | — | — | EP | disclosed |
| EP-2797927-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM IND CO LTD (KR) | 2019-09-25 | — | — | EP | disclosed |
| US-RE47451-E1 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO. LTD. (KR) | 2019-06-25 | — | — | US | disclosed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | disclosed |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | disclosed |
| EP-1773843-A4 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | UNIV TEXAS (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7285556-B2 | Thienopyrimidine-based inhibitors of the src family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1773843-A1 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | The Board of Regents of The University of Texas System (US) | 2007-04-18 | — | — | EP | disclosed |
| US-RE39267-E1 | Thienopyrimidine-based inhibitors of the SRC family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-09-05 | — | — | US | disclosed |
| WO-2006014404-A1 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20040077663-A1 | Thienopyrimidine-based inhibitors of the src family | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-22 | — | — | US | disclosed |
| US-6503914-B1 | Thienopyrimidine-based inhibitors of the Src family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | SRC, LCK, FYN | PDPK1 351/4885PARP1 2264/4885DAPK3 350/4885 |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | PDPK1 4512/4885PARP1 3379/4885DAPK3 4267/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | PDPK1 430/4885PARP1 65/4885DAPK3 625/4885 |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | PDPK1 179/4885PARP1 3082/4885DAPK3 190/4885 |
| US-20040077663-A1 | Thienopyrimidine-based inhibitors of the src family | SRC, LCK, FYN | PDPK1 639/4885PARP1 1561/4885DAPK3 661/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | PDPK1 430/4885PARP1 65/4885DAPK3 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.